Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Metabolic complications of antiretroviral therapies.

Dube MP, Sattler FR.

AIDS Clin Care. 1998 Jun;10(6):41-4.

PMID:
11365497
2.

Management of protease inhibitor-associated hyperlipidemia.

Penzak SR, Chuck SK.

Am J Cardiovasc Drugs. 2002;2(2):91-106. Review.

PMID:
14727985
3.

[Metabolic complications associated with use of protease inhibitors].

Mosnier-Pudar H.

Ann Med Interne (Paris). 2000 Jun;151(4):278-82. Review. French.

PMID:
10922955
4.

[Dysmetabolic syndrome related to HIV-1 protease inhibitors. Review of the literature and personal data].

Urso R, Croce GF, Tubili C, De Marco M, La Scala P, Luglio D, Narciso P.

Recenti Prog Med. 2000 Feb;91(2):78-85. Review. Italian.

PMID:
10748653
6.

Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.

Schambelan M, Benson CA, Carr A, Currier JS, Dubé MP, Gerber JG, Grinspoon SK, Grunfeld C, Kotler DP, Mulligan K, Powderly WG, Saag MS; International AIDS Society-USA.

J Acquir Immune Defic Syndr. 2002 Nov 1;31(3):257-75. Review.

PMID:
12439201
7.

Metabolic complications associated with antiretroviral therapy.

Jain RG, Furfine ES, Pedneault L, White AJ, Lenhard JM.

Antiviral Res. 2001 Sep;51(3):151-77. Review.

PMID:
11448728
8.

[HIV-lipodystrophy syndrome].

Mauss S, Schmutz G.

Med Klin (Munich). 2001 Jul 15;96(7):391-401. Review. German.

PMID:
11494914
9.

Drug treatment of combined hyperlipidemia.

Wierzbicki AS, Mikhailidis DP, Wray R.

Am J Cardiovasc Drugs. 2001;1(5):327-36. Review.

PMID:
14728015
10.

Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.

Calza L, Manfredi R, Chiodo F.

J Antimicrob Chemother. 2004 Jan;53(1):10-4. Epub 2003 Nov 25. Review.

PMID:
14645323
11.
12.

Tolerability and safety of HIV protease inhibitors in adults.

Sax PE, Kumar P.

J Acquir Immune Defic Syndr. 2004 Sep 1;37(1):1111-24. Review. Erratum in: J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1434.

PMID:
15319670
13.

Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents.

Fantoni M, Del Borgo C, Autore C, Barbaro G.

Ital Heart J. 2002 May;3(5):294-9. Review.

PMID:
12066561
14.

[Metabolic side effects of antiretroviral therapy].

van der Valk M, Reiss P.

Ned Tijdschr Geneeskd. 2008 May 31;152(22):1260-4. Review. Dutch.

PMID:
18590059
15.

Metabolic issues associated with protease inhibitors.

Moyle G.

J Acquir Immune Defic Syndr. 2007 Jun 1;45 Suppl 1:S19-26. Review.

PMID:
17525687
16.

Protease inhibitor-sparing simplified maintenance therapy: a need for perspective.

Bucher HC, Young J, Battegay M.

J Antimicrob Chemother. 2004 Aug;54(2):303-5. Epub 2004 Jul 21. Review.

PMID:
15269200
17.

Adverse drug reactions to protease inhibitors.

Manchanda T, Schiedel D, Fischer D, Dekaban GA, Rieder MJ.

Can J Clin Pharmacol. 2002 Fall;9(3):137-46. Review.

PMID:
12422251
18.
19.

[Epidemiology of the metabolic abnormalities in patients with HIV infections].

Mehta R, Loredo B, Sañudo ME, Hernandez-Jiménez S, Rodríguez-Carranza SI, Gómez-Pérez FJ, Rull JA, Aguilar-Salinas CA.

Rev Invest Clin. 2004 Mar-Apr;56(2):209-21. Review. Spanish.

PMID:
15377074
20.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503

Supplemental Content

Support Center